Profound, lasting structural improvement in overall skin clarity, texture, and systemic immune health when maintained strictly with proper medical UV sun protection
Semaglutide enhances vascular health by improving blood flow and reducing arterial stiffness
Its usually used for three to six weeks, although it is approved by the U.S
Eli Lilly is studying retatrutide in several phase-3 clinical trials for obesity, type-2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatosis liver disease
The compound reached Phase 2 human trials for obesity (Metabolic Pharmaceuticals, early 2000s) but never advanced to Phase 3, leaving overall human efficacy evidence rated Low quality